A proposal of a “ready to use” COVID-19 control strategy in an Oncology ward: Utopia or reality?

Dalu, Davide; Rota, Selene; Cona, Maria Silvia; Brambilla, Anna Maria; Ferrario, S.; Gambaro, Anna; Meroni, Luca; Merli, Stefania; Farina, Gabriella; Verde, Nicla La

doi:10.1016/j.critrevonc.2020.103168

Cited by 8 publications

(10 citation statements)

References 18 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Variable LogNB and LogND are statistically significant at 1% level of significance and positively influence 'Change in medical expenses with drugs' -%ED. Our results are supported by the literature in the field as well Dalu et al (2021). analyzed the Italian region Lombardy,…”

supporting

confidence: 91%

The Impact of COVID-19 on the Romanian Hospitals’ Expenses. A Case Study Toward the Financial Resilience after the Pandemic

Gyorgy

Simionescu

2021

TRAS

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID-19) affected almost all activities worldwide. The medical sector was one of those which were most significantly impacted because the medical infrastructure was not sized for such a high scale shock, specialized human resources and medical infrastructure proving to be much undersized and with slow growth potential. Many changes were required, important financial resources being mobilized in order to motivate medical staff, offer treatments for the most severely affected patients, but also to create new facilities where the increasing number of sick persons could be cured. In our research we want to offer a hospital cost perspective based on empirical analysis of the COVID-19 impact on different categories of expenses made by Romanian hospitals that treated patients with COVID-19 in different stages of their disease. The period analyzed was January 2019 to December 2020 on a monthly basis. Our results showed that expenses with goods and services, drugs, reagents and human resources are influenced by COVID-19 in a significant manner.

show abstract

supporting

confidence: 91%

The Impact of COVID-19 on the Romanian Hospitals’ Expenses. A Case Study Toward the Financial Resilience after the Pandemic

Gyorgy

Simionescu

2021

TRAS

View full text Add to dashboard Cite

show abstract

“…First of all, they recommended making a correct patient selection, categorising them into high, medium or low priority, in order to minimize hospital access for those patients who could continue the treatment/surveillance while staying at home through online medical counselling (telemedicine) or home drug delivery. For outpatients who needed to access the hospital, it was crucial to adopt all procedures aimed to reduce the risk of potential contagion, through a correct triage at the entrance of the day hospital and clinic, the use of individual protection devices and a reorganization of spaces in order to maintain social distancing [ 9 ]. The implementation of these procedures led to the unavoidable consequence that patients accessed the hospital without caregivers, who could not stay with them in the waiting room and during the visit.…”

Section: Introductionmentioning

confidence: 99%

The emotional impact of the COVID-19 outbreak on cancer outpatients and their caregivers: results of a survey conducted in the midst of the Italian pandemic

Cona

Rulli

Dalu

et al. 2021

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

Introduction The study investigates the emotional discomfort of cancer patients and their caregivers, who need to access the oncology day hospital to receive treatment during the COVID-19 pandemic in Italy. Methods This is a single-institution, prospective, cross-sectional study. From May to June 2020, the points of view of both patients and caregivers were compared through 2 different multiple-choice questionnaires, enquiring demographic characteristics, changes in emotional status, interpersonal relationships with health professionals (HCPs) and self-perception of treatment outcomes. Results Six hundred twenty-five patients and 254 caregivers were enrolled. Females were prevalent and patients were generally older than caregivers. Forty percent of patients and 25.6% of caregivers thought they were at a greater risk of contagion because lived together with a cancer patient or accessed the hospital. Both patients (86.3%) and caregivers (85.4%) considered containment measures a valid support to avoid the spread of infection. People with a lower education level were less worried about being infected with SARS-COV-2. Waiting and performing visits/treatments without caregivers had no impact on the emotional status of patients (64.4%), but generated in caregivers greater anxiety (58.8%) and fear (19.8%) of not properly managing patients at home. The majority of patients (54%) and caregivers (39.4%) thought the pandemic does not influence treatment outcomes. The relationship with HCPs was not negatively impacted for majority of patients and caregivers. Conclusions Starting from these data, we can better understand the current psychological distress of patients and their families in order to develop potential strategies to support them in this strenuous period of crisis. Supplementary Information The online version contains supplementary material available at 10.1007/s00520-021-06489-y.

show abstract

“…Early studies reported high effectiveness of both vaccines for the prevention of symptomatic COVID‐19, at 95% for BNT162b2 vaccine and 94% for mRNA‐1273. 15 , 16 These data were confirmed in subsequent real‐world vaccination campaigns, 18 , 19 , 20 although the efficacy was reduced 24‐week after the first two doses. 21 Clinical trials on the efficacy and safety of the COVID‐19 vaccine however did not include vulnerable populations, as cancer patients.…”

Section: Introductionmentioning

confidence: 57%

“…The COVID‐19 mitigation measures, such as lock down, staying at home, using facemasks, hand hygiene, physical distancing, the increased ventilation of indoor spaces and restricting protocols for hospital access had been applied but were not able to slow down the spread of the infection. 16 …”

Section: Introductionmentioning

confidence: 99%

“…14,15 The COVID-19 mitigation measures, such as lock down, staying at home, using facemasks, hand hygiene, physical distancing, the increased ventilation of indoor spaces and restricting protocols for hospital access had been applied but were not able to slow down the spread of the infection. 16 In that scenario, the protection by immunization was urgently needed. In an unprecedented way, fast track approved mRNA-based vaccines, BNT162b2 vaccine (Pfizer-BioNTech) and mRNA-1273 (Moderna), were introduced already 9 months after the declaration of the pandemic and given first to healthcare professionals and high-risk groups.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity of two doses of BNT162b2 and mRNA‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV‐2 infection

Verde

Riva

Cona

et al. 2022

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Previous studies on the immunogenicity of SARS‐CoV‐2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single‐institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA‐1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS‐CoV‐2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty‐one cancer patients had a previous exposure to SARS‐CoV‐2. Cancer patients previously exposed to the virus had significantly higher median levels of anti‐S1 and anti‐RBD IgG, compared to healthy controls ( P = .0349) and to cancer patients without a previous infection ( P < .001). Vaccine type (anti‐S1: P < .0001; anti‐RBD: P = .0045), comorbidities (anti‐S1: P = .0274; anti‐RBD: P = .0048) and the use of G‐CSF (anti‐S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS‐CoV‐2 significantly enhanced the response to vaccination (anti‐S1: P < .0001; anti‐RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS‐CoV‐2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination.

show abstract

A proposal of a “ready to use” COVID-19 control strategy in an Oncology ward: Utopia or reality?

Cited by 8 publications

References 18 publications

The Impact of COVID-19 on the Romanian Hospitals’ Expenses. A Case Study Toward the Financial Resilience after the Pandemic

The Impact of COVID-19 on the Romanian Hospitals’ Expenses. A Case Study Toward the Financial Resilience after the Pandemic

The emotional impact of the COVID-19 outbreak on cancer outpatients and their caregivers: results of a survey conducted in the midst of the Italian pandemic

Immunogenicity of two doses of BNT162b2 and mRNA‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV‐2 infection

Contact Info

Product

Resources

About